Can a Triple-Drug combo outsmart a rare and aggressive cancer?
NCT ID NCT07738159
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This clinical trial is testing whether adding two newer drugs—QL1706 and lenvatinib—to standard chemotherapy can help people with a rare and aggressive cancer called extrapulmonary neuroendocrine carcinoma (EP-NEC). The study will compare the combination against chemotherapy alone as the first treatment for people whose cancer has spread or cannot be removed with surgery. The main goal is to see if the combination delays cancer growth for at least six months, and researchers will also look at overall survival and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and tuvonralimab injection (QL1706) plus lenvatinib and etoposide-based platinum chemotherapy
- What this could lead to
- If successful, this combination could become a new first-line treatment option for extrapulmonary neuroendocrine carcinoma, potentially improving progression-free survival and overall survival.
- What could go wrong
- This is a phase 2 trial with a modest sample size, so results may not be definitive. The combination may increase side effects, and the benefit over standard chemotherapy is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could essential oils tame chemo nausea? a new trial puts aromatherapy to the test
- Shielding the ovaries: a drug may help young breast cancer patients preserve fertility during chemo
- Can surgery for stomach or esophageal cancer cloud the mind?
- Art therapy meets oncology: could mandala coloring boost cancer Patients' well-being?
- Could a chemo boost after radiation tame aggressive prostate cancer?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?